IRDOpus Genetics, Inc.
$3.46+77% 1Y
$3.46
$1.7452 weeks$6.09
Is the price fair?
What IRD's price assumes
Opus Genetics, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 46.5× revenue.
46.5
Price / sales · no P/E: the last twelve months did not end in a profit
- EV / sales
- 41.0
EV / sales
Details›
- EV / EBIToperating margin −513%: the multiple describes the denominator
- not meaningful
- EV / salesas of 2026-Q2
- 41.0
- Market capitalisation83.2 million shares, counted Aug 3, 2026
- $288M
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.